Hermetica Superfood Encyclopedia
The Short Answer
Viili's primary bioactives are phosphate-containing exopolysaccharides (EPS, termed viilian or VEPS, ~2000 kDa) produced by Lactococcus lactis subsp. cremoris, alongside ACE-inhibitory tripeptides IPP and VPP, which collectively exert antioxidant, anti-inflammatory, immunomodulatory, antihypertensive, and antitumor effects in preclinical models. In vitro studies demonstrate anti-proliferative activity against HepG2 hepatocellular carcinoma cells at 200 μg/mL VEPS, and mouse microbiome studies at 50 μg/day show significant increases in beneficial Muribaculum species and prevention of fecal butyric acid decline, though human clinical data remain limited.
CategoryOther
GroupFermented/Probiotic
Evidence LevelPreliminary
Primary Keywordviili fermented milk benefits
Viili — botanical close-up
Health Benefits
**Antihypertensive Effect**
The tripeptides IPP (Isoleucine-Proline-Proline) and VPP (Valine-Proline-Proline) generated during viili's high-proteolysis fermentation inhibit angiotensin-converting enzyme (ACE), reducing vasoconstriction; observational data from Finnish and Japanese populations with mild hypertension suggest clinically relevant blood pressure reductions.
**Antioxidant Protection**
VEPS exopolysaccharides exhibit dose-dependent free radical scavenging activity at concentrations of 0–50 μg/mL in vitro, with demonstrated synergistic enhancement when co-administered with ursolic acid, suggesting potential utility in oxidative stress mitigation.
**Anti-Inflammatory Activity**
VEPS suppresses lipopolysaccharide (LPS)-induced inflammation in RAW264.7 macrophages at concentrations of 50–200 μg/mL, as confirmed by Western blot analysis showing altered inflammatory protein expression and observable changes in macrophage morphology.
**Immunomodulation**: Oral administration of Lactococcus lactis subsp
cremoris TL1 in preclinical models promotes Th1/Th2 immune balance, elevates the regulatory cytokine IL-10, and suppresses IgE and ovalbumin-specific antibody responses, indicating potential relevance for allergic and atopic conditions.
**Antitumor Activity**
VEPS at 200 μg/mL inhibits proliferation of HepG2 human hepatocellular carcinoma cells in MTT assays, and induces cellular senescence at concentrations as low as 12.5 μg/mL, suggesting dose-dependent multi-modal anticancer mechanisms requiring further validation.
**Gut Microbiome Modulation**
Daily oral administration of 50 μg VEPS in mice significantly increases the relative abundance of Muribaculum, a beneficial short-chain fatty acid-associated genus, and prevents the characteristic decline in fecal butyric acid concentrations observed in control animals.
**Prebiotic-Like Substrate Activity**
The complex polysaccharide backbone of VEPS, comprising D-glucose, D-galactose, and L-rhamnose repeating units, may serve as a fermentable substrate for colonic microbiota, contributing to butyrate production and mucosal epithelial barrier support through indirect prebiotic mechanisms.
Origin & History
Natural habitat
Viili is a traditional fermented milk product originating from Nordic farms in Finland and Sweden, where it has been produced for centuries as a means of preserving fresh cow's milk without refrigeration. It is cultivated under mesophilic conditions at approximately 22.5°C for 24 hours, distinguishing it from thermophilic yogurts and allowing its characteristic microbial consortium to thrive. The product is defined by its ropy, viscous texture generated by exopolysaccharide-producing strains of Lactococcus lactis subsp. cremoris, which dominate the starter culture alongside accessory yeasts and fungi including Geotrichum candidum.
“Viili has been produced on Nordic farms, particularly in Finland and Sweden, for several centuries, representing one of the oldest preserved forms of mesophilic dairy fermentation in Northern Europe, where cool ambient temperatures naturally favored its slow-fermenting microbial consortium. In Finnish culinary and folk medicine tradition, viili was valued not only as a nutritious staple food but as a digestive aid and preservative product that could be maintained indefinitely by back-slopping a small portion of each batch into fresh milk, a practice that perpetuated genetically stable microbial communities across generations. A variant known as Termoviili incorporates additional organisms including Lactobacillus delbrueckii ssp. lactis and Geotrichum candidum and requires stimulation with formic acid at 7.35 mM, suggesting deliberate artisanal manipulation of the fermentation environment in different regional traditions. Viili was introduced to Japan in the early 21st century as a functional food product, where its documented ACE-inhibitory peptides attracted scientific interest from researchers studying non-pharmacological approaches to hypertension management in aging populations.”Traditional Medicine
Scientific Research
The current evidence base for viili and its VEPS bioactives is preliminary, consisting predominantly of in vitro cell culture experiments and a small number of mouse studies, with no published randomized controlled trials reporting specific sample sizes, power calculations, or quantified effect sizes in humans. Anti-inflammatory and antitumor effects of VEPS have been demonstrated in RAW264.7 macrophage and HepG2 cell assays at defined concentrations (12.5–200 μg/mL), providing mechanistic plausibility but limited translational certainty due to the absence of pharmacokinetic or bioavailability data in living organisms. A mouse microbiome study administering VEPS at 50 μg/day via drinking water documented statistically significant increases in Muribaculum abundance and prevention of butyric acid decline in young male mice on a normal diet, representing the most complete in vivo dataset available, although sample sizes were not disclosed in available sources. Antihypertensive effects of viili-derived IPP and VPP are supported by observational reports from Finnish and Japanese mildly hypertensive populations, but without published n-values, confidence intervals, or controlled trial designs, this evidence remains insufficient to establish clinical efficacy by current standards.
Preparation & Dosage
Traditional preparation
**Traditional Fermented Milk (Home/Artisanal)**
1 g of viili starter culture to 1 L of fresh cow's milk; incubate at 22
Add .5°C for 24 hours until solidified and ropy; consume as fermented dairy food in portions typical of Scandinavian dietary patterns (100–200 mL per serving).
**VEPS Research Isolate (Preclinical)**
Exopolysaccharides isolated via trichloroacetic acid (TCA) precipitation at a final yield of approximately 6.7%; administered to mice at 50 μg/day via drinking water in the sole published in vivo microbiome study.
**In Vitro Effective Concentrations**
Anti-inflammatory and antioxidant effects observed at 50–200 μg/mL VEPS; antitumor senescence induction at 12.5 μg/mL; these concentrations have no established human equivalents.
**Supplemental Form**
No standardized commercial VEPS supplement exists; no established human supplemental dose has been validated in clinical trials.
**Lactic Acid Bacteria Load**
Viili fermented milk reaches approximately 9 Log CFU/g of lactic acid bacteria post-fermentation, comparable to commercial probiotic yogurts.
**Timing**
Traditional consumption is with meals; no clinical timing data exist for isolated VEPS or peptide fractions.
**Standardization**
No pharmacopeial or commercial standardization for VEPS content has been established; EPS composition varies by strain and fermentation conditions.
Nutritional Profile
Viili as a fermented milk product provides a macronutrient profile broadly comparable to low-fat plain yogurt, with protein, fat, and carbohydrate content dependent on the milk substrate used; specific macronutrient quantification from standardized analysis is not widely published. Key bioactive constituents include lactic acid at 2.79–2.97 g/100 g, acetic acid at 0.06–0.63 g/100 g, and trace phenolic compounds quantified as gallic acid equivalents, alongside VEPS at concentrations sufficient to impart characteristic ropy texture (precise g/100 g yield varies by strain). Calcium, phosphorus, riboflavin, and vitamin B12 are expected micronutrients from the dairy base, consistent with fermented milk nutritional standards. The dominant bioactive fraction—VEPS (viilian)—comprises 29–85% carbohydrates (D-glucose, D-galactose, L-rhamnose) and 3–47% protein by composition; bioavailability of intact VEPS to systemic circulation is not established, though gut-level microbiome-modifying activity has been confirmed in mouse studies at 50 μg/day. Lactic acid bacteria reach approximately 9 Log CFU/g at end of fermentation, contributing a probiotic microbial load alongside the EPS fraction.
How It Works
Mechanism of Action
VEPS (viilian), with a molecular weight of approximately 2000 kDa and repeating units including →4-β-Glcp-(1→4)-β-D-Galp-(1→4)-β-D-Glcp-(1→ and α-L-Rhap groups, interacts with pattern recognition receptors on macrophages to modulate NF-κB and MAPK signaling pathways, suppressing pro-inflammatory cytokine release while elevating IL-10 in a concentration-dependent manner across 50–200 μg/mL. The bioactive tripeptides IPP and VPP competitively inhibit angiotensin-converting enzyme (ACE) by occupying the active site with their proline-rich C-terminal sequences, thereby preventing conversion of angiotensin I to the vasoconstrictive angiotensin II and reducing peripheral vascular resistance. VEPS antitumor activity in HepG2 cells involves induction of cellular senescence pathways at 12.5 μg/mL and antiproliferative mechanisms at 200 μg/mL, potentially including cell cycle arrest and modulation of senescence-associated secretory phenotype (SASP), though precise molecular targets such as p21 or p53 have not yet been fully characterized. Gut-level activity of orally administered VEPS at 50 μg/day appears to involve selective enrichment of Muribaculum spp. and preservation of colonic butyrate pools, implicating short-chain fatty acid receptor signaling (GPR41/GPR43) and histone deacetylase inhibition as downstream effectors of observed anti-inflammatory and epithelial-protective outcomes.
Clinical Evidence
No formal human randomized controlled trials for viili VEPS as an isolated ingredient have been identified in the peer-reviewed literature with reported sample sizes or quantified effect sizes. Antihypertensive outcomes attributed to viili-derived IPP and VPP tripeptides have been noted in Finnish and Japanese subjects with mild hypertension, but these reports lack the methodological detail required to assess effect magnitude, statistical significance, or confounding control. Preclinical mouse data at 50 μg/day VEPS provide the strongest controlled evidence, demonstrating significant microbiome shifts and butyrate preservation, outcomes with theoretical relevance to metabolic and inflammatory disease prevention. Overall clinical confidence is low; viili is best characterized as a functional food with mechanistically plausible benefits that require adequately powered human trials before therapeutic claims can be substantiated.
Safety & Interactions
No adverse effects have been reported in either preclinical mouse studies at 50 μg/day VEPS or in populations consuming traditional viili as part of Nordic dietary patterns, and the product's long history of human consumption supports a favorable general safety profile for healthy adults. As a high-LAB fermented dairy food (up to 9 Log CFU/g), viili carries the standard precautions applicable to live-culture dairy products: individuals who are severely immunocompromised, post-organ-transplant, or receiving immunosuppressive therapy should consult a physician before consuming high-load probiotic foods due to theoretical risk of bacteremia from translocating organisms. No specific drug interactions have been formally studied for viili-derived VEPS or IPP/VPP peptides; however, the ACE-inhibitory activity of IPP and VPP warrants theoretical caution when consumed in large or concentrated amounts alongside prescribed ACE inhibitor medications (e.g., lisinopril, enalapril) due to potential additive blood pressure reduction. No contraindications specific to pregnancy or lactation have been identified; fermented dairy consumption is generally considered safe in pregnancy, though individuals with lactose intolerance or milk protein allergy should avoid this product, as fermentation does not eliminate allergenic caseins or whey proteins.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Viili (Lactococcus lactis subsp. cremoris / Leuconostoc mesenteroides)Long milkRopy fermented milkNordic ropy milkViilian (EPS fraction)VEPSLactococcus lactis subsp. cremoris fermented milk
Frequently Asked Questions
What makes viili different from regular yogurt?
Viili is fermented by mesophilic bacteria, primarily Lactococcus lactis subsp. cremoris, at a low temperature of 22.5°C, unlike thermophilic yogurt cultures that require 42–45°C. This slow fermentation produces unique phosphate-containing exopolysaccharides (VEPS, ~2000 kDa) that give viili its characteristic ropy, stretchy texture and distinct bioactive properties not found in conventional yogurt. Additionally, viili may contain accessory organisms such as Geotrichum candidum and yeasts, further diversifying its microbial and biochemical profile.
Does viili lower blood pressure?
Viili contains ACE-inhibitory tripeptides IPP (Isoleucine-Proline-Proline) and VPP (Valine-Proline-Proline), generated during its high-proteolysis fermentation, which inhibit the enzyme that converts angiotensin I to the vasoconstrictive angiotensin II. Observational reports from Finnish and Japanese subjects with mild hypertension suggest blood pressure reduction associated with viili consumption, but no published randomized controlled trial has quantified the effect size or reported sample sizes. Individuals on prescribed ACE inhibitor medications should consult a physician before consuming viili regularly due to potential additive blood pressure-lowering effects.
What are VEPS or viilian exopolysaccharides?
VEPS (viili exopolysaccharides), also termed viilian, are large phosphate-containing polysaccharide molecules (~2000 kDa) secreted by Lactococcus lactis subsp. cremoris during fermentation, composed of 29–85% carbohydrates (D-glucose, D-galactose, L-rhamnose) and 3–47% protein. They are responsible for viili's distinctive viscous texture and are the primary bioactive fraction studied for antioxidant, anti-inflammatory, antitumor, and gut microbiome-modulating effects. In preclinical research, VEPS has been tested at concentrations of 12.5–200 μg/mL in cell studies and 50 μg/day in mouse microbiome experiments.
Is viili safe to eat every day?
Viili has a long history of daily consumption in Finland and Sweden without reported adverse effects in healthy populations, and mouse studies administering isolated VEPS at 50 μg/day found no adverse outcomes. As a high-LAB fermented food reaching approximately 9 Log CFU/g, it carries standard precautions for severely immunocompromised individuals, who should seek medical advice before consuming high-load live-culture dairy products. People with lactose intolerance or casein milk protein allergy should avoid viili, as fermentation does not fully eliminate these allergens.
Can viili improve gut health?
In a mouse study, oral administration of 50 μg/day of viili VEPS significantly increased the abundance of Muribaculum, a beneficial short-chain fatty acid-associated gut bacterium, and prevented the characteristic decline in fecal butyric acid concentrations compared to controls. Butyrate is a critical colonocyte energy substrate that supports intestinal barrier integrity and suppresses colonic inflammation via histone deacetylase inhibition and GPR41/GPR43 receptor signaling. While these preclinical findings are mechanistically compelling, equivalent human clinical data are not yet available, and viili's gut health effects in humans remain to be established through controlled trials.
Does viili contain live probiotics, and do they survive digestion?
Yes, viili contains live Lactococcus lactis subsp. cremoris cultures that are viable probiotics, though not all cells survive stomach acid to reach the colon. The exopolysaccharides (VEPS) produced by these bacteria may provide prebiotic benefits even if some organisms are inactivated during digestion. Regular consumption of viili helps maintain a steady population of these beneficial strains in the gut microbiota.
How does the fermentation process in viili affect its nutritional profile compared to fresh milk?
Viili's extended fermentation with Lactococcus lactis dramatically increases its proteolysis, breaking down milk proteins into bioactive peptides like IPP and VPP that are absent in fresh milk. This fermentation also reduces lactose content, making viili easier to digest for lactose-sensitive individuals, and increases the bioavailability of certain minerals like calcium and magnesium. The fermentation also generates beneficial compounds like lactic acid and exopolysaccharides that provide additional health benefits.
Is viili an effective alternative to ACE inhibitor medications for blood pressure management?
While viili's bioactive tripeptides (IPP and VPP) do inhibit ACE similarly to pharmaceutical ACE inhibitors, clinical evidence suggests it produces modest blood pressure reductions best suited for mild hypertension as a complementary dietary approach rather than a medication replacement. Viili should not be substituted for prescribed blood pressure medications without medical supervision, though it may provide additive benefits when incorporated into a hypertension management plan. The magnitude of effect is typically smaller than pharmaceutical ACE inhibitors, making it most valuable for individuals seeking dietary interventions or those with borderline elevated blood pressure.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w viili-lactococcus-lactis-subsp-cremoris-fermented-milk curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
